Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics announced an expanded FDA approval for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) in patients aged 4 and above. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients. The continued approval for non-ambulatory patients hinges on the results of a confirmatory trial. ELEVIDYS is contraindicated for patients with mutations in exon 8 and/or exon 9 of the DMD gene. Sarepta's ENVISION study aims to verify the clinical benefits of ELEVIDYS. The expansion represents a significant milestone for the Duchenne community and gene therapy.
Sarepta Therapeutics (NASDAQ:SRPT) announced on May 31, 2024, the issuance of equity awards as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The awards were given to nine newly hired employees, granting a total of 8,975 restricted stock units (RSUs). The RSUs will vest in four equal installments annually over four years, subject to continuous employment. The awards were part of Sarepta's 2024 Employment Commencement Incentive Plan and approved by the Compensation Committee of the Board of Directors. No stock purchase options were granted.
Sarepta Therapeutics, Inc. announced that Dr. Jerry R. Mendell, a gene therapy pioneer, was named to the inaugural TIME100 Health list for his contributions in neuromuscular disease treatment and gene therapy advancements, notably Duchenne muscular dystrophy. Dr. Mendell's lifelong dedication to genetic medicine has significantly impacted global health.
Sarepta Therapeutics reported strong financial results for the first quarter of 2024, with net product revenues totaling $359.5 million, a 55% increase from the prior year. ELEVIDYS gene therapy generated $133.9 million in revenue. The company achieved GAAP earnings of $36.1 million and non-GAAP earnings of $78.2 million. Real-world evidence showed that eteplirsen treatment resulted in significant survival benefits for Duchenne muscular dystrophy patients. The FDA is reviewing an efficacy supplement to expand ELEVIDYS's indication.
Sarepta Therapeutics, Inc. granted equity awards under Nasdaq Listing Rule 5635(c)(4) to 24 new employees in April 2024, comprising options to purchase 0 shares of common stock and 17,090 restricted stock units. The options have an exercise price of $126.66 per share, with vesting schedules spread over four years.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.